glp-1 for iih The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial PDF) Effect of GLP ‐1

If you have both diabetes and obesity, a GLP-1 addresses both at the same time

GLP-1 Agonists Market size was valued at US$ 37,113.2 billion in 2025 and is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026-2032

In ATTAIN-1, adverse event-related discontinuation rates were 5.3% with orforglipron 6 mg, 7.6% with 12 mg, and 10.3% with 36 mg, compared with 2.7% with placebo

Regarding obesity management, coverage for semaglutide may be more limited, as it was originally developed as a diabetes medication

This process protects the peptide until researchers are ready to use it